Glossary · Treatments

Estradiol patch

Also called: Climara, Vivelle-Dot, Minivelle, Estradiol transdermal patch.

Definition: Transdermal estradiol patches deliver estradiol through the skin at a steady rate, typically replaced once or twice weekly. Doses range from 0.025 mg/day to 0.1 mg/day. Patches bypass first-pass hepatic metabolism, which avoids the modest increase in venous thromboembolism risk associated with oral estrogen, making them a preferred first-line systemic estrogen for many menopausal women.

Detailed definition

Estradiol transdermal patches use a matrix or reservoir delivery system to release estradiol at a controlled rate through skin. The most common products release 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day, applied to the lower abdomen or buttock. Patches are changed once weekly (e.g., Climara) or twice weekly (e.g., Vivelle-Dot, Minivelle). Compared to oral estradiol, transdermal delivery produces steadier serum levels, avoids first-pass hepatic metabolism, and does not raise SHBG or coagulation factor production the same way — translating to a smaller (and often clinically negligible) thrombotic risk. NAMS, the British Menopause Society, and the Endocrine Society all favor transdermal estradiol over oral estrogen for women with thromboembolic risk factors. For women with an intact uterus, patches must be paired with progesterone or a progestin for endometrial protection.

Why it matters in menopause

Estradiol patches are the workhorse of modern systemic HRT. They are well-tolerated, dose-flexible, and do not require remembering a daily pill. Most ClearedRx patients on systemic HRT use a patch as their estrogen delivery method.

Sources

External references: Wikipedia.

← Back to full glossary